NEW YORK (GenomeWeb News) – Agendia today said that it has signed a contract with Blue Shield of California, making it an in-network provider.
The deal, Agendia said, opens the way for other Blue Cross affiliates nationwide to cover Agendia's tests including its MammaPrint. Other payors, including Medicare, Humana, and United Healthcare, also have coverage policies for MammaPrint, and the company has contracts with Palmetto, Humana, Coventry and other national preferred provider organization plans.
MammaPrint, Agendia's lead product, is a gene expression signature assay for determining which patients with breast cancer may be at risk of metastases. The test can help guide treatment decisions.
The Dutch molecular diagnostics firm filed for an initial public offering in Europe in June but shelved it two weeks later citing adverse market conditions. Most recently David Macdonald replaced Bernhard Sixt as Agendia's CEO.